TransMedics Completes OrganOx Acquisition
Ticker: TMDX · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1756262
| Field | Detail |
|---|---|
| Company | Transmedics Group, Inc. (TMDX) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $13.9 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, medical-devices, milestone-payments
TL;DR
TransMedics just bought OrganOx for $20M cash + stock, plus potential $100M milestones. Big move for transplant tech.
AI Summary
TransMedics Group, Inc. announced the completion of its acquisition of OrganOx Limited on December 5, 2024. The acquisition was previously disclosed on October 26, 2024, and involved an upfront payment of $20 million in cash and 1,000,000 shares of TransMedics common stock. The deal also includes potential milestone payments of up to $100 million.
Why It Matters
This acquisition expands TransMedics' organ transplant technology portfolio, potentially enhancing its market position and future revenue streams in the medical device sector.
Risk Assessment
Risk Level: medium — The inclusion of significant potential milestone payments introduces future financial uncertainty and execution risk.
Key Numbers
- $20.0M — Upfront Cash Payment (Part of the acquisition consideration for OrganOx)
- 1.0M shares — Stock Issued (Part of the acquisition consideration for OrganOx)
- $100.0M — Potential Milestone Payments (Additional payments contingent on future performance)
Key Players & Entities
- TransMedics Group, Inc. (company) — Acquiring company
- OrganOx Limited (company) — Acquired company
- $20 million (dollar_amount) — Upfront cash payment
- 1,000,000 shares (dollar_amount) — Stock issued as part of acquisition
- $100 million (dollar_amount) — Potential milestone payments
- December 5, 2024 (date) — Completion date of acquisition
- October 26, 2024 (date) — Date of previous disclosure of acquisition
FAQ
What is the primary strategic rationale behind TransMedics' acquisition of OrganOx?
The filing implies the acquisition is to expand TransMedics' organ transplant technology portfolio, though specific details are not elaborated in this 8-K.
What was the total upfront consideration paid by TransMedics for OrganOx?
The total upfront consideration was $20 million in cash and 1,000,000 shares of TransMedics common stock.
When was the acquisition of OrganOx officially completed?
The acquisition was completed on December 5, 2024.
Are there any future payments associated with the OrganOx acquisition?
Yes, there are potential milestone payments of up to $100 million.
Was the acquisition of OrganOx previously disclosed?
Yes, the acquisition was previously disclosed on October 26, 2024.
Filing Stats: 666 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2024-12-09 16:07:28
Key Financial Figures
- $13.9 million — . for a purchase price of approximately $13.9 million (together with the Prior Acquisitions,
Filing Documents
- d900251d8k.htm (8-K) — 24KB
- 0001193125-24-273403.txt ( ) — 139KB
- tmdx-20241205.xsd (EX-101.SCH) — 3KB
- tmdx-20241205_lab.xml (EX-101.LAB) — 17KB
- tmdx-20241205_pre.xml (EX-101.PRE) — 11KB
- d900251d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRANSMEDICS GROUP, INC. Date: December 9, 2024 By: /s/ Gerardo Hernandez Name: Gerardo Hernandez Title: Chief Financial Officer and Treasurer